Emcure Pharmaceuticals Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Net profit of Emcure Pharmaceuticals rose 28.81% to Rs 243.40 crore in the quarter ended March 2026 as against Rs 188.96 crore during the previous quarter ended March 2025. Sales rose 16.70% to Rs 2469.70 crore in the quarter ended March 2026 as against Rs 2116.25 crore during the previous quarter ended March 2025.

For the full year,net profit rose 35.67% to Rs 924.36 crore in the year ended March 2026 as against Rs 681.33 crore during the previous year ended March 2025. Sales rose 16.56% to Rs 9203.54 crore in the year ended March 2026 as against Rs 7896.00 crore during the previous year ended March 2025.

Powered by Capital Market - Live News

Emcure Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 5 May 2026, inter alia, have recommended the final dividend of Rs 3.6 per equity Share (i.e. 36%) , subject to the approval of the shareholders.

Emcure Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 5 May 2026.

Emcure Pharmaceuticals has announced the price revision of its weight management drug Poviztra? (semaglutide injection) across India.

The reduced price would be starting at Rs. 3,999/- per month (4 weekly doses).

The innovator Semaglutide is available in a once-weekly pen device in five strengths of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a maintenance dose of 2.4 mg. It comes in a state-of-the-art pen device that provides the convenience of simple administration and precise dosing.

As the first Indian company to exclusively distribute and commercialise Poviztra?, a second brand of Novo Nordisk's semaglutide injection for obesity, Emcure aims to expand access and enable more patients to benefit from this proven therapy at the revised price.